Washington Trust Advisors’s Cytokinetics CYTK Stock Holding History

Washington Trust Advisors’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-49	Closed	-$2.69K	–	611
2025 Q3	$2.69K	Hold	49	–	–	﹤0.01%	649
2025 Q2	$1.62K	Hold	49	–	–	﹤0.01%	617
2025 Q1	$1.97K	Hold	49	–	–	﹤0.01%	613
2024 Q4	$2.31K	Hold	49	–	–	﹤0.01%	615
2024 Q3	$2.59K	Hold	49	–	–	﹤0.01%	624
2024 Q2	$2.65K	Hold	49	–	–	﹤0.01%	619
2024 Q1	$3.44K	Hold	49	–	–	﹤0.01%	614
2023 Q4	$4.09K	Hold	49	–	–	﹤0.01%	589
2023 Q3	$1.44K	Hold	49	–	–	﹤0.01%	656
2023 Q2	$1.6K	Hold	49	–	–	﹤0.01%	633
2023 Q1	$1.73K	Hold	49	–	–	﹤0.01%	736
2022 Q4	$2.25K	Hold	49	–	–	﹤0.01%	717
2022 Q3	$2K	Buy	+49	New	+$2.36K	﹤0.01%	847

Other funds holding CYTK

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Washington Trust Advisors's CYTK Position: Q4 2025 in Review

Washington Trust Advisors sold out of Cytokinetics (CYTK) in Q4 2025, closing a stake of 49 shares — an estimated $2.69K sold.

Washington Trust Advisors first reported a position in CYTK in Q3 2022 and held it in 13 quarters. The position peaked at $4.09K in Q4 2023. 431 funds tracked by Wall St. Rank hold CYTK as of Q4 2025.

Washington Trust Advisors reported no remaining Cytokinetics position as of Q4 2025 after selling out during the quarter.
Washington Trust Advisors sold 49 Cytokinetics shares in Q4 2025, an estimated $2.69K.
Washington Trust Advisors first reported a position in Cytokinetics in Q3 2022 and held it in 13 quarters.
Washington Trust Advisors's Cytokinetics position peaked at $4.09K in Q4 2023.
431 funds tracked by Wall St. Rank held Cytokinetics as of Q4 2025.

Based on Washington Trust Advisors's 13F filing for Q4 2025, filed 3 Feb 2026.